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Abstract The campomelic dysplasia/autosomal sex reversal
protein SOX9 is an important developmental transcription
factor, required for correct bone and testis formation. Through
in vitro and in vivo studies we have identified the heat shock
protein HSP70 as an interacting partner for SOX9 in
chondrocyte and testicular cell lines. HSP70 forms a ternary
complex with DNA-bound SOX9. The interaction between
HSP70 and SOX9 is ATP-independent and involves a highly
conserved region of SOX9 hitherto of unknown function and the
C-terminal region of HSP70. Our results implicate HSP70^
SOX9 interactions in the assembly of multi-protein complexes
during SOX9-mediated transcription. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
SOX proteins are related to the mammalian testis-determin-
ing factor, SRY, via their HMG domain which binds and
bends DNA [1,2]. The 65 kDa SOX protein, SOX9, binds a
10 base DNA consensus sequence and also possesses two
transactivation domains at the C-terminal region of the pro-
tein, the PQS and PQA domains (for a review of SOX9, see
[3,4]). In humans, haploinsu⁄ciency of SOX9 causes campo-
melic dysplasia (CD), characterised by extreme skeletal and
cartilage malformation, and male to female sex reversal in
approximately 75% of XY individuals [5,6]. CD individuals
also have defects in the brain, heart, lung and kidneys ^ sug-
gesting the critical importance of SOX9 for correct develop-
ment. Over the past 4 years, in vivo and in vitro studies have
demonstrated that SOX9 regulates a number of genes in both
chondrogenesis and testis formation. A ¢rm link has been
established between SOX9 and two important genes involved
in chondrogenesis, namely type II collagen, Col2a1 [7,8], and
type XI collagen, Col11a2 [9]. SOX9 appears to act together
with two other proteins, L-SOX5 and SOX6, binding cooper-
atively to an enhancer region that is present in both genes
[10]. Curiously, although SOX9 is the only member of the
three SOX genes that possesses a potent transactivation do-
main, its presence on the enhancer element is necessary but
not su⁄cient for gene transcription to occur [10]. Currently
the mechanism by which the three proteins activate transcrip-
tion is unknown, although the activation of the enhancer by
SOX9 is phosphorylation state-dependent [11]. Recently an-
other gene involved in chondrogenesis, Aggrecan, has also
been implicated in regulation by SOX9 [12]. In the Sertoli
cells of the mammalian testis, SOX9 activates the anti-Mu«l-
lerian hormone (also known as Mu«llerian inhibiting sub-
stance) gene, AMH. There exist conserved binding sites for
SOX9, SF-1 (or steroidogenic factor 1) and GATA-4 in the
minimal AMH promoter [13,14], and protein^protein interac-
tions between SOX9 and SF-1 (13), SF-1 and the Wilms’
tumour protein, WT1 [15], and SF-1 and GATA-4 [16] all
contribute to the activation of the AMH gene. However,
knock-in mutations of the SOX9 and SF-1 binding sites of
the AMH promoter in mice have shown that only by ablating
the SOX9 binding site is it possible to completely eliminate
AMH activation [17].
The ubiquitous HSP70 chaperones represent a family of
heat shock proteins of approximately 70 kDa in molecular
weight. The HSP70 family are involved in the ATP-dependent
refolding of denatured proteins following heat stress (reviewed
in [18]). However, HSP70 is also implicated in a number of
completely unrelated cellular processes. These include uncoat-
ing clathrin pits on the cell membrane [19], the activation of
the steroid hormone complexes (reviewed in [20]), and a num-
ber of roles in DNA replication and gene transcription. It is
now thought that HSP70 is involved in transcriptional activa-
tion by the glucocorticoid receptor (GR) since the chaperone
is tightly bound to the GR:glucocorticoid response element
complex [21] ; and levels of nuclear HSP70 regulate the DNA
binding activity of the AP-1 transcription factor complex [22].
Interestingly, an association between the bacterial homologue
of HSP70, DnaK, and viral DNA replication has long been
established [23], where DnaK appears to function by aiding
the correct association of proteins within a multi-protein com-
plex. This has also been observed with the human papilloma-
virus in eukaryotes [24] suggesting that a role of HSP70 in
multi-protein complex formation has been conserved. Most
signi¢cantly for this study, though, is the observation of a
strong interaction between WT1 and HSP70 that has been
shown by some elegant in vivo studies to be vital for the
correct control of cell cycle by WT1 [25] although the exact
mechanism remains unknown.
Considering that WT1 is also involved in AMH activation
during vertebrate sex determination, we were interested to
determine whether WT1 and/or its closely interacting factor
HSP70 could interact with SOX9. Here we present evidence
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that HSP70 also interacts with SOX9 in an ATP-independent
fashion, and that this interaction may have implications on
SOX9-mediated transactivation, not only in the ¢eld of sex
determination, but in all transcriptional processes controlled
by SOX9.
2. Materials and methods
2.1. Production of wild-type full-length SOX9 and deletion mutants
HA-tagged full-length SOX9 and deletion mutants SOX9(vPQA)
and SOX9(1^235) were produced as described previously [26]. Dele-
tion mutant SOX9(1^400) was produced through a HindIII/PvuII di-
gest of the vector pBS-HA-SOX9 [26] ligated into a HindIII/EcoRV
digest of pcDNA3 (Invitrogen). Proteins were produced in vitro using
a TNT kit (Promega). A small proportion of each sample was trans-
lated with the incorporation of [35S]methionine to verify that proteins
of the correct molecular mass had been translated. SOX9 HMG box
was expressed recombinantly in Escherichia coli and puri¢ed as de-
scribed previously [27].
2.2. Electromobility shift assay (EMSA)
The sequence of the upper strand used for the oligonucleotide
probes (SOX9CON) was GGGTTAACAGAACAATGGAATCT-
GGT-AGA. The sequence of the SOX binding site is shown in bold
type; £anking residues giving additionally speci¢c SOX9 binding are
underlined [27]. Probes were labelled as described previously [27].
EMSA was carried out as described in [27] with the following mod-
i¢cations: in vitro translated proteins and HSP70 were incubated
at 4‡C for 15 min in 12 Wl total of binding bu¡er, then for an addi-
tional 20 min at 4‡C following the addition of 33P-labelled DNA
(V0.4 nM). Antibodies raised against HSP70 were pre-incubated
with the HSP70 protein at room temperature for 15 min prior to
addition to the reaction mixture. Protein^DNA complexes were
resolved on 6% non-denaturing polyacrylamide gels run at 350 V
(V35 mA) for 1.5 h. Gels were visualised and complexes were quan-
titated by PhosphorImager analysis (Fuji). When ATP or ADP was
added to the reaction mixture, 10 mM MgCl2 and 1 mM dithiothrei-
tol were also present in the binding bu¡er.
2.3. Western blot analysis
Protein samples were blotted on Hi-Bond nitrocellulose membrane
(Amersham) and detected as described previously [8], using 1:1000 or
1:2000 dilutions of primary antibodies and 1:1000 or 1:2000 dilutions
of horseradish peroxidase-conjugated secondary antibodies. Blots
were visualised by the ECL chemiluminescence detection kit (Amer-
sham).
2.4. Immunoprecipitation
Whole cell extracts made from RCS cells (2.5 mg) were incubated
for 2 h at 4‡C with 1 Wg of an K-SOX9 primary antibody or an
irrelevant antibody control, prior to the addition of protein A agarose
(Amersham) and subsequent rotation at 4‡C overnight. Protein A
immunoprecipitates were centrifuged and washed three times in
TBST bu¡er, before being boiled in 2ULaemmli bu¡er.
2.5. Cell types and culture
The testicular teratocarcinoma cell line, NTera2/D1, and the rat
chondrosarcoma cell line, RCS, cells were cultured as a monolayer
in Dulbecco’s modi¢ed Eagle’s medium, supplemented with 1% (v/v)
penicillin/streptomycin, 1% (v/v) L-glutamine and 10% (v/v) foetal calf
serum at 37‡C under 5% CO2.
2.6. Immunocytochemistry
Cells were grown in chamber slides for 24^48 h, washed three times
in phosphate-bu¡ered saline (PBS) and ¢xed in 2% paraformaldehyde
in PBS for 30 min. Following washing in PBS, cells were permeabi-
lised in 0.5% Nonidet P40 in PBS for 5 min with agitation, washed,
and incubated in blocking bu¡er (5% goat and 5% horse serum di-
luted in incubation bu¡er (1 mM CaCl2, 3% globulin-free bovine
serum albumin, 0.5% Triton X-100 in PBS)) for 30 min at room
temperature. Slides were washed and then incubated overnight in a
1:100 dilution of SAM K-SOX9 and N15 K-HSP70 antibodies in in-
cubation bu¡er overnight at 4‡C. Following washing, slides were in-
cubated in 1:200 dilutions of FITC-conjugated anti-rabbit and Texas
red-conjugated anti-mouse secondary antibodies (Vector) in incuba-
tion bu¡er at room temperature for 2 h. Slides were washed and
visualised under a Leica £uorescent microscope or a Leica laser-scan-
ning confocal microscope.
Fig. 1. HSP70 forms a ternary complex with SOX9 and DNA, inde-
pendent of ATP concentration. A: In an EMSA reaction, in vitro
translated human HA-tagged SOX9, and recombinant human
HSP72 or partially puri¢ed mouse Hsp73 were incubated together
prior to the addition of a 33P-labelled DNA probe. The anti-HSP70
antibodies were pre-incubated with HSP72 or Hsp73 prior to being
added to the reaction mixture. Lane 6 contains the addition of a
complete protease inhibitor mix. In vitro translated luciferase was
used as a control (lanes 1 and 2). The asterisk in lane 7 indicates
the presence of an antibody^SOX9^DNA species. B: In an EMSA
reaction, in vitro translated SOX9 was incubated with either 0, 1 or
5 mM ATP, with (lanes 4^6) and without (lanes 1^3) the presence
of HSP70 in the reaction mix. The slowly migrating band above the
HSP70^SOX9^DNA complex is possibly artefactual SOX9 dimer as
observed previously [26].
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2.7. Bioinformatic tools
Secondary structure for the SOX9 protein was predicted via the
Predict Protein Server based on the PHD analysis algorithms [28].
Sequence alignments were performed using the ClustalW algorithm
[29] and displayed using the ES-Pript server [30].
3. Results
To test a possible interaction between HSP70 and SOX9,
HSP70 was incubated with the SOX9^DNA complex run on
EMSA gels, using in vitro translated human SOX9 and re-
combinant human HSP70 (Fig. 1A). The addition of 1^2 WM
of HSP70 caused the appearance of a band that migrated
more slowly than the SOX9^DNA complex (lane 4), suggest-
ing that a ternary complex was formed between HSP70, SOX9
and DNA. Both the inducible and cognate isoforms of HSP70
were able to form the ternary complex, suggesting that com-
plex formation was not speci¢c to a particular HSP70 isoform
(data not shown). It should be noted that the concentration of
HSP70 used in this system is comparable with the concentra-
tions required to interact with the AP-1 transcription factor
complex in vitro (0.7^1.4 WM) [22] and for maximal steroid
hormone foldosome assembly with the glucocorticoid receptor
in vitro (V3 WM) [31]. Unlike with AP-1, HSP70 appears to
have no e¡ect upon the DNA binding activity of SOX9. To
determine whether the putative HSP70^SOX9^DNA complex
did indeed contain HSP70 and SOX9, antibodies raised
against both HSP70 and the HA tag of SOX9 were pre-in-
cubated with the reaction mixture. Addition of an HSP70
antibody (clone N6) resulted in a supershift of the HSP70^
SOX9^DNA complex (lane 6), while the addition of an anti-
body raised against the HA tag of the in vitro translated
SOX9 caused a supershift of both the SOX9^DNA (asterisk)
and HSP70^SOX9^DNA complexes (lane 7). Taken together,
these results suggest that HSP70 can recognise DNA-bound
SOX9. Anti-HSP70 antibodies have been raised which recog-
nise di¡erent domains of HSP70. Clone N6 recognises an epi-
tope between amino acids 373^430 of the HSP70 substrate
binding domain (data not shown and R. Anderson, personal
communication). The binding of N6 to HSP70 had no e¡ect
upon the HSP70^SOX9 interaction as revealed by the super-
shift (lane 6). In contrast, a second HSP70 antibody, clone
N15, recognises an epitope between amino acids 540 and 650
of the HSP70 C-terminus (data not shown and R. Anderson,
personal communication). Pre-incubation of HSP70 with N15
speci¢cally blocked the interaction between HSP70 and SOX9
(lane 5), implying that the region of HSP70 recognised by N15
(amino acids 540^650) is also involved in SOX9 binding.
Because of the inherent ability of heat shock proteins to
bind to any denatured or incorrectly folded substrate in an
ATP-dependent manner, it was investigated whether the inter-
action observed between HSP70 and SOX9 arose merely
through the binding of HSP70 to denatured or incorrectly
folded SOX9 caused by the in vitro translation process. The
ability of HSP70 to bind to denatured or incorrectly folded
proteins is known to be dependent upon ATP/ADP concen-
trations ^ at high (s 1 mM) concentrations of ATP, HSP70
fails to bind to a hydrophobic substrate, whereas an increase
in ADP concentrations will cause a stronger binding of
HSP70 to the substrate [32,33]. However, although very
high concentrations of ATP were observed to cause a gradual
reduction in SOX9^DNA binding, increasing ATP concentra-
tions to 5 mM was not observed to cause a reduction in the
formation of the HSP70^SOX9 multiprotein complex at 4‡C
(Fig. 1B) or at 37‡C (data not shown). Furthermore, substi-
tuting 1 mM ADP into the reaction mixture was also observed
to have no e¡ect on complex formation (data not shown). We
conclude that the interaction between HSP70 and SOX is not
dependent on ATP or ADP concentrations, and thus not
likely to be an artefact resulting from the binding of HSP70
to denatured protein.
To identify the region of SOX9 that interacts with HSP70,
the HSP70 binding ability of a number of deletion mutants of
SOX9 was tested by EMSA (Fig. 2A). Deletions spanning
most of the PQS domain (v401^509) or the PQA domain
(v333^402) both retained the ability to bind HSP70. In con-
trast, neither puri¢ed SOX9 HMG box (100^180) nor the N-
terminal half of the protein (1^235) exhibited any HSP70
binding activity. The region of SOX9 that interacts with
HSP70 thus appears to lie within a stretch of 96 amino acids
between residues 236 and 332 ^ a region of the protein that
Fig. 2. Identi¢cation of the HSP70 interacting region of SOX9.
A: Deletion analysis of the interaction between SOX9 and HSP70.
In EMSA reactions, the following proteins were analysed for an
interaction with HSP70: full-length SOX9; SOX9(1^401);
SOX9(v333^401); SOX9(1^235); puri¢ed SOX9 HMG box (101^
184). Proteins were incubated with the DNA alone (3) or following
pre-incubation with HSP70 (+). Black arrowheads show the position
of the SOX9^DNA band; white arrowheads mark the presence of
the HSP70^SOX9^DNA complex if present. B: Conservation of the
HSP70 interacting region of SOX9. SOX9 from nine vertebrate spe-
cies (human ^ accession number P48436; pig ^ O18896; mouse ^
S52469; chicken ^ P48434; alligator ^ Q9YGP7; frog ^ BAA95427;
trout ^ O57395; zebra¢sh ^ AAG 09814, turtle ^ [41]) SOX8 from
three species (human ^ AF228664; mouse ^ AW244736; chicken ^
AF228664) and SOX10 from four species (human ^ XM009977; rat
^ NM019193; chicken ^ AF152356; mouse ^ AF017182) were
aligned using ClustalW; residues completely conserved across the
three proteins are represented by a black line; homologous substitu-
tions are represented by a stippled line. The HMG box, PQS and
PQA domains and HSP70 interacting region are boxed.
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has no previously known function and which is highly con-
served in both SOX9 and the two related SOX proteins,
SOX8 and SOX10 (Fig. 2B).
Since an interaction between HSP70 and SOX9 was dem-
onstrated in vitro by EMSA, it was investigated whether such
an interaction could be supported by co-immunoprecipitation
of SOX9 from cultured cells. Immunoprecipitates of SOX9
within whole cell extracts from a rat chondrosarcoma line,
RCS, were observed to contain a 70 kDa band, detectable
with an K-HSP70 antibody (N6) that co-migrated with
HSP70 found in the extract (Fig. 3A). In contrast, HSP70
was not found to co-precipitate with a non-speci¢c rabbit
polyclonal antibody (raised against FD-bacteriophage). At-
tempts to perform the reverse experiment were unsuccessful
owing to a failure to immunoprecipitate HSP70. This evidence
thus supports the above in vitro studies, and suggests that
SOX9 and HSP70 interact under physiologically relevant con-
ditions found in mammalian cells in vivo.
In order to determine whether the two proteins co-localised
in vivo, we examined the distribution of HSP70 and SOX9 in
mammalian cell lines. Both proteins were found to exhibit
strong nuclear staining in two cell lines known to express
SOX9, the chondrocyte cell line RCS and a human Sertoli-
like teratocarcinoma cell line, NTera2/D1 (NT2), using
immunocytochemistry (Fig. 3B). In the RCS cell line, both
HSP70 and SOX9 exhibited punctate co-localisation within
the nucleus, but not the nucleoli, of RCS cells (Fig. 3C).
Curiously, in the NT2 cell line SOX9 exhibited de¢ned punc-
tate staining within the cell nucleoli as well, an observation
which has not been described previously and which was not
seen with HSP70 (Fig. 3C). While both proteins showed some
co-localisation outside the nucleoli, this was not to the same
degree as that observed with the RCS cell line and raises the
possibility that other interacting factors may mediate the in-
teraction in this cell line. No background immuno£uorescence
was detectable in cells incubated without primary antibodies
(data not shown). This result thus supports the earlier in vitro
and co-immunoprecipitation studies, and suggests that SOX9
and HSP70 may be present within the nuclei of SOX9 express-
ing cells as part of a multi-protein complex.
4. Discussion
The results described above present strong evidence for an
interaction between SOX9 and HSP70. The two proteins were
found to interact as part of a multi-protein complex on DNA,
through a speci¢c interaction that did not appear to be
through the process of HSP70 binding to denatured or incor-
rectly folded SOX9 protein. That the in vitro association be-
tween SOX9 and HSP70 may have a physiological basis can
be seen through two results. Namely, that HSP70 was found
to co-immunoprecipitate with SOX9 protein, and that the two
proteins exhibited strong co-localisation within the nuclei of a
SOX9-expressing cell line. While SOX9 is well established as
an important developmental protein, HSP70 also exhibits tis-
sue-speci¢c expression during development. The heat shock
protein co-localises to urogenital tissue that also expresses
WT1 [25], suggesting that HSP70 should be expressed in the
developing Sertoli cells that express both WT1 and SOX9.
Furthermore, during endochondral bone formation HSP70
mRNA is developmentally expressed weakly in the resting
and strongly in the proliferative phases of chondrogenesis
Fig. 3. Characterisation of the interaction between SOX9 and
HSP70 in vivo. A: Co-immunoprecipitation of HSP70 with SOX9.
Whole cell extracts from RCS cells (2.5 mg) were immunoprecipi-
tated with either anti-SOX9 or irrelevant antibodies. Samples were
washed and analysed via SDS^PAGE and immunoblotting with an
anti-HSP70 antibody. A proportion of the whole cell lysate was in-
cluded as a positive control. Molecular mass markers (in kDa) are
indicated to the left of the ¢gure. B: Localisation of SOX9 and
HSP70 to the nucleus of RCS and NT2/D1 cell lines. Immunocyto-
chemical staining of HSP70 in red and SOX9 in green as visualised
under a £uorescent microscope. Scale bar: 50 Wm. C: Localisation
of SOX9 and HSP70 within the nucleus of RCS and NT2/D1 cell
lines. Immunocytochemical staining of SOX9 in green, HSP70 in
red or both as visualised under a confocal laser scanning micro-
scope. Scale bar: 5 Wm.
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[34] ^ the two stages of chondrogenesis in which type II col-
lagen and SOX9 mRNA are most strongly expressed [10,35].
In contrast, HSP70 mRNA is absent in hypertrophic chon-
drocytes [34] which also have little or no SOX9 expression
[35]. The reason for the presence of HSP70 during this early
stage of chondrogenesis is unknown, and we suggest that one
reason may be a speci¢c role in SOX9-mediated gene activa-
tion. Such evidence implies a strong link between SOX9 and
HSP70 expression during development.
Through the use of deletion mutants of SOX9, it has been
determined that HSP70 interacts with a 96 amino acid stretch
of the SOX9 protein ^ a region which lies outside both the
DNA binding and transactivation domains of SOX9. The
region that interacts with HSP70 is highly conserved, both
in SOX9 and in the two related SOX genes, SOX8 and
SOX10. However, this region exhibits little homology to any
other protein outside the SOX transcription factors. We sug-
gest that an interaction with HSP70 has been one reason
behind such a high degree of conservation in this region,
and that it is highly probable that both SOX8 and SOX10
will also interact with HSP70. The ability of a speci¢c anti-
HSP70 antibody to block the interaction between HSP70 and
SOX9 suggested that SOX9 binds to the carboxy-terminus of
the heat shock protein, between amino acids 540 and 650.
This K-helical domain of HSP70 is a region that appears to
be involved in protein^protein interactions, as it is already
known to interact with the proteins Hip [36], Hop (or p60)
[37] and Chip [38]. These interact with HSP70 via a tetratri-
copeptide repeat (or TPR) domain ^ a 34 amino acid domain
that consists of a helix-turn-helix motif [39]. However, analy-
sis of the secondary structure of the HSP70 binding region of
SOX9 using the PredictProtein server [28] showed the chance
of any helical structure being present within this region is
extremely low. We therefore suggest that SOX9 interacts
with the C-terminus of HSP70 via a novel motif.
Although some sequence speci¢city within SOX proteins
may exist [27], protein^protein interactions are likely to be
vital for the speci¢c regulation of di¡erent genes in di¡erent
tissues by the SOX transcription family [40]. SOX9, in partic-
ular, is known to form part of a greater multi-protein complex
for the regulation of both the collagen genes and AMH. It is
possible that an interaction with HSP70 in this context may
aid the correct association of SOX9 with other proteins upon
these regulatory elements. With respect to viral DNA replica-
tion, HSP70 appears to play a vital role in governing the
correct formation of multi-protein complexes [23,24], and we
suggest that such a mechanism may also be employed in
SOX9-mediated gene regulation. Another, more speci¢c way
in which an interaction between HSP70 and SOX9 may be
signi¢cant can be seen in the process of mammalian sex de-
termination. The regulation of the crucial AMH gene is con-
trolled not only by SOX9 and SF1 [13], but also by WT1 [15].
However, while binding sites to both SOX9 and SF1 are con-
served within the AMH promoter, WT1 has no conserved
binding site and it interacts with SF1 only very weakly. Con-
sidering that WT1 strongly interacts with HSP70 [25] it is
possible to speculate that WT1 binding at the AMH promoter
is stabilised by the formation of a SOX9^HSP70^WT1 protein
complex. The fact that SOX9 and SF1 also interact raises the
possibility that the four proteins may form a tightly associated
complex at this promoter. In conclusion, we describe here an
interaction between SOX9 and HSP70 that occurs while
SOX9 is bound to DNA and may have implications for the
control of gene regulation by SOX9 during development.
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